Clinical Trial

Effects of Tranexamic Acid Irrigation on Impacted Third Molar Surgery

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Tranexamic acid (TXA) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. It is a relatively safe drug with minimal significant side effects. The most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. The increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. Based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. To mitigate systemic absorption and minimize undesirable side effects, TXA can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-31.
Trial Details
NCT Number NCT06806241
Lead Sponsor Bezmialem Vakif University
Conditions Bleeding, Tooth Extraction
Enrollment 20 participants
Start Date 2025-01-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-24